While Materialise's Q1 results were mixed, they exceeded low investor expectations, with the company's Medical segment continuing to excel. Market conditions are likely to remain challenging, but ...

Materialise continues to grow on the back of its Medical segment, which is expanding at a rapid pace. Materialise's margins will continue to improve going forward, driven by a combination of revenue ...

Stratasys PolyJet technology and Materialise FDA-cleared software now most versatile 3D printing system for hospitals and physicians to build anatomical models at the point-of-care MINNEAPOLIS & ...

CHICAGO--(BUSINESS WIRE)--TVT2019 – Structural Heart Summit --Materialise (NASDAQ:MTLS), a global 3D printing software and solutions company, has received FDA clearance for its Mimics Enlight ...

The CE Marking approval indicates that a medical device meets the requirements of the European Medical Devices Directive. Until now, Materialise’s personalized devices made use of the custom-made ...

Further bringing 3D printed medical models to life, Stratasys is expanding the suite of printers and materials validated by its collaborator Materialise as part of FDA-cleared Materialise Mimics ...